Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer
Journal of Experimental Medicine · 2024
DOI: 10.1084/jem.20240435 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2024. Verfasst von Zhen Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Acrylamides, Telomerase, Aniline Compounds, ErbB Receptors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The inevitable acquired resistance to osimertinib (AZD9291), an FDA-approved third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR activating or T790M resistant mutations, limits its long-term clinical benefit. Telomere maintenance via telomerase reactivation is linked to uncontrolled cell growth and is a cancer hallmark and an attractive cancer therapeutic target. Our effort toward understanding the action mechanisms, including resistance mechanisms, of osimertinib has led to the identification of a novel and critical role in maintaining c-Myc–dependent downregulation of hTERT, a catalytic subunit of telomerase, and subsequent inhibition of telomerase/telomere and induction of telomere dysfunction in mediating therapeutic efficacy of osimertinib. Consequently, osimertinib combined with the telomere inhibitor, 6-Thio-dG, which is currently tested in a phase II trial, effectively inhibited the growth of osimertinib-resistant tumors, regressed EGFRm NSCLC patient-derived xenografts, and delayed the emergence of acquired resistance to osimertinib, warranting clinical validation of this strategy to manage osimertinib acquired resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA.
- Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China.
- Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
ORCID-Profile: Zhen Chen, Karin A Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang, Ticiana Leal, Suresh S Ramalingam, Shi-Yong Sun
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Chen, Z., Vallega, K. A., Wang, D., Quan, Z., Fan, S., Wang, Q., Leal, T., Ramalingam, S. S., & Sun, S. Y. (2024). Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20240435
Vancouver
Chen Z, Vallega KA, Wang D, Quan Z, Fan S, Wang Q, et al. Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer. Journal of Experimental Medicine. 2024. doi:10.1084/jem.20240435
BibTeX
@article{Chen2024,
author = {Chen, Zhen and Vallega, Karin A and Wang, Dongsheng and Quan, Zihan and Fan, Songqing and Wang, Qiming and Leal, Ticiana and Ramalingam, Suresh S and Sun, Shi-Yong},
title = {Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer},
journal = {Journal of Experimental Medicine},
year = {2024},
doi = {10.1084/jem.20240435}
}
EUVIMED